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Abstracts
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Spectrometry, Translational Genomics Research Institute, Phoenix, AZ, 
USA, 2Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
CA, USA, 3Department of Medicine, University of California San Diego, 
La Jolla, CA, USA, 4Moores Cancer Center, University of California San 
Diego, La Jolla, CA, USA
Medulloblastoma (MB) is classified into four molecular subgroups: wing-
less (WNT), sonic hedgehog (SHH), Group 3 (G3) and Group 4 (G4), each 
with different molecular profiles and patient outcomes. Subgroup hetero-
geneity and low mutational burdens have hindered the identification of ac-
tionable therapeutic targets, especially in G3 MB which has a particularly 
poor prognosis. Therefore, we took a (phospho)-proteomics approach to 
identify active pathways and potential therapeutic opportunities in twenty 
orthotopic patient-derived xenograft (PDX) models of MB comprising SHH, 
G3 and G4 subtypes. Through our enrichment analysis, we identified pro-
cesses and pathways specifically upregulated in each MB subgroup. We also 
utilized neural network derived kinase-substrate predictions and kinase ac-
tivity scores inferred by a heuristic machine learning algorithm to further 
characterize phosphosignaling activity. We found that MB PDX models 
recapitulate many features of primary MB tumors including two distinct 
proteomic subtypes of G3. G3a was enriched for transcription, transla-
tion and MYC target genes while G3b was enriched for axon guidance and 
neurotrophin signaling pathways. Notably, both G3a and G3b contained 
higher abundance of mitochondrial proteins, suggesting altered tumor me-
tabolism in G3 MB. SHH PDXs displayed increased NFκB and JNK-MAPK 
signaling. Group 4 MBs most closely resembled differentiated neuronal cells 
and were enriched for PKC and AMPK signaling as well as DNA repair 
pathways. In conclusion, we have provided a comprehensive proteomic and 
phosphoproteomic characterization of commonly studied MB PDX models 
and revealed new insights into subgroup enriched pathways and kinase ac-
tivity in MB.
OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA 
VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING
Dean Thompson1, Jemma Castle2, Debbie Hicks2, Steve Clifford2, and 
Ed Schwalbe1; 1Northumbria University, Newcastle upon Tyne, UK, 
2Newcastle University, Newcastle upon Tyne, UK
Introduction: International consensus recognises four molecular sub-
groups of medulloblastoma, each with distinct molecular features and 
clinical outcomes. The current gold-standard for subgroup assignment is 
DNA methylation microarray. There is an unmet need to develop platform-
independent subgrouping assays which are both non-proprietary and 
compatible with rapidly-expanding WGS capacity in healthcare. Whole 
Genome Bisulfite Sequencing (WGBS) enables the assessment of genome-
wide methylation status at single-base resolution. Previously, WGBS adop-
tion has been limited by cost and sample quality/quantity requirements. Its 
application for routine detection of medulloblastoma subgroups has not 
previously been reported.  Methodology: Two datasets were utilised; 36 
newly-sequenced low-depth (10x coverage) and 34 publicly-available high-
depth (30x) WGBS medulloblastomas, all with matched DNA methylation 
microarray data. We compared platform concordance and identified mo-
lecular subgroups. Machine-learning WGBS-based subgroup classifiers were 
optimised and compared between platforms. Aneuploidy and mutation de-
tection using WGBS was optimised and compared to microarray-derived 
estimates where possible. Finally, comprehensive subgroup-specific DNA 
methylation signatures were identified. Results: We optimised a pipeline for 
processing, quality control and analysis of low-depth WGBS data, suitable 
for routine molecular subgrouping and aneuploidy assessment. We demon-
strated the suitability of fresh-frozen and FFPE DNA for WGBS, and, using 
downsampling, showed that subgroup calling is robust at coverages as low 
as 2x. We identified differentially methylated regions that, due to poor rep-
resentation, could not be detected using methylation microarrays. Molecular 
subgroups of medulloblastoma assigned using WGBS were concordant with 
array-based definitions, and WGBS-derived classifier performance meas-
ures exceeded microarray-derived classifiers.  Conclusion: We describe a 
platform-independent assay for molecular subgrouping of medulloblastoma 
using WGBS. It performs equivalently to current array-based methods at 
comparable cost ($405 vs $596) and provides a proof-of-concept for its 
routine clinical adoption using standard WGS technology. Finally, the full 
methylome enabled elucidation of additional biological heterogeneity that 
has hitherto been inaccessible.
OMIC-07. FEASIBILITY AND UTILITY OF EPIGENOMIC PROFILING 
FOR CHILDHOOD CNS TUMORS IN HONG KONG
Anthony P.Y. Liu1,2, Ronnie S.L. Ho3, Kay K.W. Li4, Shing Chan2, 
Dennis T.L. Ku1, Eric Fu1, Chung-Wing Luk1, Jeffrey P.W. Yau1,  
Siu-Cheung Ling5, Brian H.Y. Chung2, Wanling Yang2, Amanda Kan6, 
Matthew M.K. Shing1, Ho-Keung Ng4, and Godfrey C.F. Chan1,2; 
1Department of Paediatrics and Adolescent Medicine, Hong Kong 
Children’s Hospital, Hong Kong, Hong Kong, 2Department of Paediatrics 
and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University 
of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, 
3Department of Pathology, Queen Mary Hospital, Hong Kong, Hong 
Kong, 4Department of Anatomical and Cellular Pathology, Faculty of 
Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 
5Department of Paediatrics and Adolescent Medicine, Princess Margaret 
Hospital, Hong Kong, Hong Kong, 6Department of Pathology, Hong Kong 
Children’s Hospital, Hong Kong, Hong Kong
Genome-wide DNA methylation profiling has emerged as an important 
diagnostic tool that complements histopathology for CNS tumors in children 
and adults. Literature describing its application in Asian countries is none-
theless limited. Herein, we report the feasibility and utility of adopting such 
platform for children diagnosed with CNS tumors in Hong Kong. A multi-
institutional cohort (n=94, 97% of Chinese ethnicity) with CNS embryonal or 
high grade neuroepithelial tumors (HGNET) diagnosed in Hong Kong from 
1996–2020 was assembled based on tissue availability. DNA was extracted 
from FFPE tumor material (median 301ng, range 13-1000ng), bisulfite con-
verted and profiled with the Infinium Methylation EPIC BeadChip kit. Raw 
data were analyzed on the German Cancer Research Center MNP 2.0 clas-
sifier and through unsupervised dimensionality-reduction analysis (t-SNE) 
referencing a published CNS tumor reference dataset (GSE90496). The radio-
histologic diagnosis included medulloblastoma (n=65), ATRT (n=9), pineal 
parenchymal tumors (n=7), ETMR (n=5), CNS-PNET (n=4) and other embry-
onal tumors/HGNETs (n=4). Methylation class could be assigned based on 
results from MNP 2.0 (calibrated score ≥ 0.9) in 62 patients (66%, including 
2 clustering with control) and t-SNE in 22 (23%), while no-match was en-
countered in 10 (11%). Methylation-based analysis allowed confirmation of 
diagnosis and assignment of molecular subgroup in 64 patients (68%), con-
firmation of histologic diagnosis alone in 5 (5%) and resulted in revision/
reassignment of diagnosis in 13 (14%). Among medulloblastoma samples 
that were assigned molecular tumor classes (n=57), 8 clustered with WNT-
activated medulloblastoma, 13 with SHH-activated medulloblastoma, 10 with 
Group 3 medulloblastoma, 21 with Group 4 medulloblastoma, and 5 with 
non-medulloblastoma entities (high-grade gliomas=3, ETMR=1, ATRT=1). In 
conclusion, epigenomic profiling allowed refinement of disease classification 
for pediatric CNS tumors. Availability of such methodology in Asia sets the 
stage for international collaborations in molecularly-driven trials.
OMIC-08. COMPOUND HETEROZYGOSITY OF POLE AND PMS2 
LEADS TO CMMRD-LIKE PHENOTYPE- “POLYNCH” SYNDROME
Orli Michaeli1, Hagay Ladany2, Yosef E Maruvka2, Ayelet Erez3, 
Shay Ben Shachar4,5, Shai Izraeli6,7, Yael Goldberg8,7, and 
Helen Toledano1,7; 1Pediatric Hematology Oncology Division,Schneider 
Children’s MEdical Center of Israel, Petach Tikva, Israel, 2Technion - Israel 
Institute of Technology, Haifa, Israel, 3Weizmann Institute of Science, 
Rechovot, Israel, 4Clalit Research Institute, Ramat Gan, Israel, 5Schneider 
Children’s MEdical Center of Israel, Petach Tikva, Israel, 6Pediatric 
Hematology Oncology Division, chneider Children’s MEdical Center 
of Israel, Petach Tikva, Israel, 7Sackler Faculty of Medicine, Tel Aviv 
University, Tel Aviv, Israel, 8Raphael Recanati Genetic Institute, Rabin 
Medical Center–Beilinson Hospital, Petach Tikva, Israel
Mono-allelic germline pathogenic variants (PV) in one of the mismatch 
repair (MMR) system genes cause Lynch syndrome, associated mainly with 
colon and endometrial cancer in adults. Germline PVs in DNA polymerase 
epsilon (POLE) are associated with a dominantly inherited syndrome which 
confers risk for polyposis and colon cancer. Brain tumors have been de-
scribed as part of Lynch syndrome and POLE associated syndrome, mostly 
in adults. Constitutional mismatch repair deficiency (CMMRd) is caused 
by bi-allelic mutations in the MMR genes, associated with multiple café 
au lait macules (CAMs) and high incidence of pediatric cancer, including 
brain tumors. Both MMRD and POLE associated tumors have high tumor 
mutation burden (TMB), however, microsatellite status is usually unstable 
in MMR tumors, and stable in POLE. Germline POLE and CMMRd tu-
mors have different mutational signatures, as is signature of MMR tumors 
with secondary somatic POLE. We describe a 4.5 y/o male who presented 
with a grossly metastatic SHH-activated, TP53-wildtype desmoplastic 
medulloblastoma. Physical examination was noted for CAMs. Family his-
tory was positive for a heterozygous POLE variant with variable clinical 
manifestations. Immunohistochemistry of the tumor showed loss of nuclear 
expression of the MMR gene PMS2, specifically in tumor cells. Analysis 
showed exceptionally high TMB (up to 276 Mut/Mb) and both the MMR 
and the POLE signatures. Germline analysis detected the familial POLE 
variant as well as a de novo heterozygous PMS2 PV. The phenotype of the 
patient together with the tumor’s features, led us to classify this case as a 
CMMRd-like. The patient had a partial response to intensive chemotherapy 
and is currently on immunotherapy without radiation. Collectively, our data 
suggest that heterozygous simultaneous germline mutations in MMR and 
polymerase genes can lead to novel “POLYNCH syndrome” that manifests 
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